PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 51 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $0 | – | 17 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 17 | -99.2% | 0.00% | – |
| Q1 2022 | $3,000 | – | 2,017 | +11764.7% | 0.00% | – |
| Q4 2021 | $0 | – | 17 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | -100.0% | 17 | -100.0% | 0.00% | – |
| Q2 2021 | $285,000 | +16.3% | 76,606 | +8.1% | 0.00% | – |
| Q1 2021 | $245,000 | +77.5% | 70,874 | +72.8% | 0.00% | – |
| Q4 2020 | $138,000 | +590.0% | 41,006 | +616.6% | 0.00% | – |
| Q3 2020 | $20,000 | -13.0% | 5,722 | +13.3% | 0.00% | – |
| Q2 2020 | $23,000 | +53.3% | 5,049 | +14.7% | 0.00% | – |
| Q1 2020 | $15,000 | -58.3% | 4,401 | -26.7% | 0.00% | – |
| Q4 2019 | $36,000 | +89.5% | 6,005 | +33.5% | 0.00% | – |
| Q3 2019 | $19,000 | -60.4% | 4,498 | +19.3% | 0.00% | – |
| Q2 2019 | $48,000 | – | 3,769 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |